TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet-fed

2 mouse

- 4 Stella Bernardi¹, Barbara Toffoli², Veronica Tisato³, Fleur Bossi¹, Stefania Biffi², Andrea Lorenzon⁴,
- 5 Giorgio Zauli³, Paola Secchiero³, Bruno Fabris¹
- ¹Department of Medical Sciences, Università degli Studi di Trieste, Cattinara Teaching Hospital,
- 8 Strada di Fiume 447, 34100 Trieste
- ²Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", via dell'Istria 65, 34137 Trieste,
- 10 Italy

14

3

- ³Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, Università degli
- 12 Studi di Ferrara, Via Fossato di Mortara 66, 44100 Ferrara
- ⁴Cluster in Biomedicine, CBM S.c.r.l., Area Science Park, Trieste, Italy
- 15 Word count: 4011
- 16 *Corresponding author*:
- 17 Stella Bernardi MD, PhD
- Department of Medical Sciences, Università degli Studi di Trieste, Cattinara Teaching Hospital, Strada
- di Fiume 447, 34100 Trieste, Italy
- 20 E: stella.bernardi@asuits.sanita.fvg.it/shiningstella@gmail.com
- 21 P: (+39)3339534214 / (+39)0403994236
- 22 F: (+39)0403994493

Abstract

- 24 Aims/hypothesis: Recent studies suggest that a circulating protein called TRAIL (TNF-related
- 25 apoptosis-inducing ligand) may have an important role in the treatment of type 2 diabetes. It has been
- shown that TRAIL deficiency worsens diabetes and that TRAIL delivery, when it is given before
- 27 disease onset, slows down its development. This study aimed at evaluating whether TRAIL had the
- potential not only to prevent, but also to treat type 2 diabetes.
- 29 Methods: Thirty male C57BL/6J mice were randomized to a standard or a high-fat diet (HFD). After 4
- weeks of HFD, mice were further randomized to receive either placebo or TRAIL, which was delivered
- 31 weekly for 8 weeks. Body weight, food intake, fasting glucose and insulin were measured at baseline
- and every 4 weeks. Tolerance tests were performed before drug randomization and at the end of the
- study. Tissues were collected for further analyses. Parallel *in vitro* studies were conducted on HepG2
- 34 cells and mouse primary hepatocytes.
- 35 Results: TRAIL significantly reduced body weight, adipocyte hypertrophy, free fatty acid levels and
- 36 inflammation. Moreover, it significantly improved impaired glucose tolerance, and ameliorated non-
- 37 alcoholic fatty liver disease (NAFLD). TRAIL treatment reduced liver fat content by 47% in vivo as
- well as by 45% in HepG2 cells and by 39% in primary hepatocytes. This was associated with a
- 39 significant increase of liver PGC-1α expression both *in vivo* and *in vitro*, pointing to a direct protective
- 40 effect of TRAIL on the liver.
- 41 Conclusion/interpretation: This study confirms the ability of TRAIL to attenuate significantly diet-
- 42 induced metabolic abnormalities, and it shows for the first time that TRAIL is effective also when
- 43 administered after disease onset. In addition, our data sheds light on TRAIL therapeutic potential not
- only against impaired glucose tolerance, but also against NAFLD.

- **Keywords**: high-fat diet, impaired glucose tolerance, type 2 diabetes, NAFLD, NASH, mouse model,
- 46 TRAIL, PPARγ, PGC-1α.

Abbreviation list

- 48 AOX, Acyl-CoA oxidase; ATG7, autophagy-related protein 7; CPT carnitine palmitoyl transferase;
- 49 CPT1a, carnitine palmitoyl transferase-1a; CRP, C-reactive protein; CYT SYNT, cytrate synthase; FAS
- 50 fatty acid synthase; gp91phox is a subunit of NADPH oxidase; HFD, high-fat diet; IPITT,
- 51 intraperitoneal insulin tolerance test; HNF4, hepatocyte nuclear factor 4; MCP1, monocyte
- 52 chemoattractant protein-1; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic
- 53 steatohepatitis; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1 alpha; pgWAT,
- 54 perigonadal white adipose tissue; PLN5, perilipin 5; PPARα, peroxisome proliferator-activated
- receptor-α; PPARγ, peroxisome proliferator-activated receptor-γ.; SIRT1, sirtuin-1; SREBP1a, sterol
- regulatory element binding protein-1a; SREBP1c, sterol regulatory element binding protein-1c;
- 57 TRAIL, TNF-related apoptosis-inducing ligand; UCP2, uncoupling protein.

Introduction

59

TRAIL is an acronym for TNF-related apoptosis-inducing ligand, which is a circulating protein 60 belonging to the TNF superfamily. Like other members of this family, such as FasL and TNFα, TRAIL 61 has the ability to induce programmed cell death (apoptosis). However, as compared to them, TRAIL 62 hits preferentially transformed cells, such as cancer cells, while sparing the normal ones (1). In non-63 malignant cells, TRAIL actions remain largely unexplored. 64 Recent experimental evidence suggests that TRAIL has significant metabolic effects (2, 3), and might 65 be involved in the regulation of obesity and diabetes mellitus, as well as their complications. The first 66 studies reporting TRAIL beneficial effects on diabetes were carried out in models of type 1 diabetes 67 and showed that TRAIL attenuated disease development and progression (4, 5) with partial 68 preservation of islet morphology (6). More recently, we reported that TRAIL delivery significantly 69 reduced the metabolic abnormalities of an experimental model of type 2 diabetes (7). Consistent with 70 these observations, other groups have shown that genetic lack of TRAIL worsened both forms of 71 72 diabetes and their associated diseases (8), such as atherosclerosis (8) and non-alcoholic fatty liver 73 disease (NAFLD) (9). The high-fat diet (HFD)-fed mouse is one of the models suitable for the study of type 2 diabetes (10). 74 After a few weeks, the HFD usually increases body weight and fat mass, leading to peripheral insulin 75 resistance and impaired glucose tolerance, with subsequent hyperglycemia and hyperinsulinemia (10). 76 Although the HFD-fed mouse does not always develops diabetes, but rather impaired glucose 77 tolerance, it has the advantage of reproducing the human situation more accurately than genetic models 78 79 of obesity-induced diabetes (11). Moreover, it allows for the study of common and burdensome diabetic comorbidities, such as obesity, NAFLD, and non-alcoholic steatohepatitis (NASH) (12). 80

A few years ago, we reported that TRAIL significantly ameliorated the metabolic abnormalities of the HFD-fed mouse. In that paper, TRAIL treatment was started before the development of metabolic abnormalities, following a preventive treatment schedule. In this study, we aimed at evaluating the therapeutic potential of TRAIL against type 2 diabetes. For this reason, TRAIL treatment was started after the development of metabolic abnormalities, following a therapeutic schedule. Here we report the effects of TRAIL treatment on glucose tolerance and on the tissues regulating it.

Materials and Methods

Recombinant human TRAIL (rhTRAIL)

- 91 Recombinant histidine 6-tagged human TRAIL (114-281) was produced in transforming bacteria BL21
- 92 with a pTrc-His6 TRAIL vector, as described (13) and detailed in the Supplementary Material and
- 93 **Methods**.

89

90

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Experimental protocol

As reported in **Figure 1A**, thirty 8-week-old C57BL/6J male mice (Harlan Laboratories, Udine, Italy) were randomized to receive either a standard diet (CNT, n=10) or a high-fat diet (HFD, n=20) for 12 weeks. After 4 weeks from diet randomization, HFD mice were randomly allocated to receive either saline (HFD, n=10) or rhTRAIL (HFD + TRAIL, n=10) for the remaining 8 weeks. CNT mice received saline (NaCl 0.9%) as well. rhTRAIL (TRAIL) was given at a dose of 10 μg/200μL per mouse by weekly intraperitoneal (IP) injection. Standard diet provided 22% of calories from protein, 66% of calories from carbohydrate, and 12% of calories from fat, and a digestible energy of 3.0 Kcal/g (Tekland Global 16% Protein Rodent Diet, Harlan Laboratories). HFD provided 18.4% of calories from protein, 21.3% of calories from carbohydrate, and 60% of calories from fat, and a digestible energy of 5.1 Kcal/g (TD 06.414 Adjusted calories diet 60/fat, Harlan Laboratories). Animals were kept (5/cage) in ventilated cabinets (Tecniplast Spa, Buggiate, Varese, Italy), in specific-pathogen-free and temperature-controlled rooms (22°C), with relative humidity of 50-70%, on a 12h light/12h dark cycle. They had free access to food and water, and they were fed ad libitum for the length of the study. During the 12-week study period, body weight, food intake, glucose, and insulin were measured at baseline and at 4-week intervals. Tolerance tests were performed before drug randomization and at the end of the study. At the end of the study, animals were anesthetized by an IP injection of tiletamine/zolazepam

(80mg/kg). Blood was collected from the left ventricle, centrifuged, and serum was stored for further 111 analyses (total cholesterol, HDL cholesterol, triglycerides, free fatty acids, C-reactive protein). 112 Pancreas, perigonadal white adipose tissue (pgWAT), liver, and quadriceps were weighed and either 113 snap frozen or fixed in formalin for further analyses. 114 The Guide for the Care and Use of Laboratory Animals, 8th edition (2011), as well as specific 115 European (86/609/EEC) and Italian (D.L.116/92) laws were followed. In compliance with the principle 116 of reducing as much as possible the number of mice studied, we did not include CNT mice + TRAIL 117 because we have previously observed and reported that repeated injections of TRAIL (providing a 118 cumulative dose of 100 µg/mouse) did not affect glucose, insulin, and/or body weight in normal 119 conditions in vivo (6). This study was approved by the Institutional Animal Care and Use Committee of 120 the Cluster in Biomedicine (CBM) and by the Italian Ministry of Health (DM 17/2001 A dd. 121

Assessment of TRAIL biodistribution

122

123

131

02/02/2011). The study period was June 2015-May 2017.

In order to evaluate TRAIL bioavailability when delivered by IP injection, 20-week-old C57BL/6J male mice (n=3) received 10 μg of Cy5.5-TRAIL by IP injection, and fluorescence in the peritoneal cavity was acquired at baseline and after 30 minutes, 6 hours, and 30 hours post-injection, as previously reported (14). The details of TRAIL labeling are in the **Supplementary Materials and Methods**. In addition, 20-week-old C57BL/6J male mice (n=8) received 10 μg of TRAIL by IP injection, bloods were collected at baseline and after 6, 30, 48, and 72 hours, and TRAIL was measured by ELISA (R&D; #DTLR00).

General parameters and biochemistries

Food intake was measured by placing in the cages pellets previously weighed in total. The food that was left over was collected and weighed to find the amount eaten. Energy intake was measured according to the digestible energy provided by both diets. Fasting glucose was measured by glucometer (Glucomen LX Plus, Menarini). Fasting insulin was measured by ELISA (Millipore; #EZRMI-13K). NEFA concentrations were measured by colorimetric assay (Sigma; #MAK044-1KT). Circulating total cholesterol, HDL cholesterol, and triglycerides were measured with the AU5800 analyzer (Beckman Coulter) by enzymatic colorimetric method, while C-reactive protein (CRP) was measured by immunoturbidimetric method.

Tolerance tests

The intraperitoneal glucose tolerance test (IPGTT) was performed on day 1 of week 4 and week 12 by injecting glucose (2 g/kg) intraperitoneally after an overnight fast. Glucose and insulin were measured at baseline and at 15, 60, and 120 min. The intraperitoneal insulin tolerance test (IPITT) was performed on day 1 of week 3 and week 11 by injecting insulin (1 unit/kg) intraperitoneally after a 6-hour fast. Glucose was measured at baseline, and at 30, 60, and 120 min.

Tissue Stainings

Adipocyte area was measured on pgWAT paraffin sections (4 μ m) stained with H&E. pgWAT macrophages were detected by F4/80 immunostaining (1:100 dilution, applied overnight; Abcam #Ab111101) and reported as positive nuclei/100 nuclei. Pancreatic beta cell density and mass were estimated as previously described (15) on paraffin sections (4 μ m) by insulin immunostaining (1:100 applied overnight; DAKO #A0564). Liver steatosis was evaluated on frozen sections (5 μ m) stained with Oil-Red-O, where fat was quantified as % of positive (red) staining/tissue area. The same method was used for skeletal muscle fat content. For liver fibrosis, paraffin sections (4 μ m) were stained with

Picrosirius Red, and fibrosis was quantified as % of positive (red) staining/tissue area (15). Liver macrophages were detected on frozen sections (5 μm) by CD68 immunostaining (1:50 applied overnight; Serotec #MCA1957S), and they were reported as positive nuclei/frame. Liver PGC-1α expression was measured on paraffin sections (4 μm) by PGC-1α immunostaining (1:50 applied overnight; Abcam #ab191838) and was reported as the % of positive (brown) staining/tissue area. All the sections were examined by light microscopy (Carl Zeiss - Jenaval) and digitized using a high-resolution camera (Q-Imaging Fast 1394). The % of staining/tissue area was quantified using Image-ProPlus 6.3 (Media Cybernetics, Bethesda, MD, USA). Quantifications were performed on 40-100 frames per group.

Liver triglyceride content

For liver triglycerides (TG), 100 mg of liver were homogenized in 1 ml of 5% NP40. Samples were heated at 95° for 5 minutes, cooled down at RT for 5 minutes twice, and then centrifuged to collect the supernatants. Triglycerides were measured with the AU5800 analyzer (Beckman Coulter) by enzymatic colorimetric method (for details, see the **Supplementary Materials and Methods**).

Gene expression quantification by RT-qPCR

Gene expression was determined by real-time quantitative RT-qPCR. In order to isolate mRNA, tissue was homogenized and processed as previously reported (16). Then, mRNA was treated to eliminate DNA contamination (Ambion DNA-free product #AM-1906), and 3 μg of treated mRNA were subsequently used to synthesize cDNA with Superscript First Strand synthesis system for RT-PCR (Gibco BRL). The gene expression of *Fas*, *Srebp1a*, *Srebp1c*, *Acox*, *Cpt1a*, *Ppara*, *Irs2*, *Pepck*, *Pparγ*, *Hnf4*, *Citrate synthase*, *Pgc-1α*, *Ucp2*, *Sirt*, *Pln*, *Gp91phox*, *Il-6*, *Tnfα*, and *Atg7* was analyzed by RT-qPCR using the SYBR Green system (Life Technologies). *Mcp1* was analyzed using the Taqman

system (Life Technologies). Fluorescence for each cycle was quantitatively analyzed by StepOnePlus real-time PCR system (Applied Biosystems). Gene expression was normalized to *Rps9* or *18s*. Results are reported as ratio compared with the level of expression in untreated controls, which were given an arbitrary value of 1. Primers are reported in **Supplementary Table 1**.

In vitro studies on HepG2 cells and mouse primary hepatocytes

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

Human hepatocellular carcinoma cells (HepG2) obtained from ATCC were cultured in high glucose DMEM, supplemented with 10% (v/v) fetal bovine serum, L-glutamine (2mM), penicillin (100U/mL), and streptomycin (100 µg/mL) in a 5% CO₂ atmosphere at 37°C. In order to mimic a high-fat diet milieu, cells were grown in media supplemented with either BSA-conjugated palmitate (250 mM) or BSA-conjugated oleate (250 mM). Cells were cultured for 24 hours with BSA-conjugated oleate with or without TRAIL (1 ng/mL) for cell viability, lipid accumulation, and protein expression studies, while they were cultured for 6 hours for gene expression analysis. Cell viability was assessed with the MTT assay (Alfa Aesar; #L11939). Total intracellular lipid content was evaluated by Oil-Red-O staining. Protein expression of PGC-1a was analyzed by immunofluorescence. Gene expression of PPARy, PGC-1a, and ATG7 was analyzed by RT-qPCR using the SYBR Green system (Life Technologies). cDNA was synthesized as detailed for our in vivo analyses. Fluorescence for each cycle was quantitatively analyzed by StepOnePlus real-time PCR system (Applied Biosystems). Gene expression was normalized to GADPH or Rpl27, and reported as a ratio compared to the level of expression in untreated controls, which were given an arbitrary value of 1. Primers are reported in Supplementary Table 1. In addition, in parallel in vitro studies, mouse primary hepatocytes were isolated from C57BL/6J male mice following a protocol adapted from Severgnini (17). After digestion with collagenase IV, liver suspension was passed through a cell strainer. Primary hepatocytes were washed 4 times and seeded on

pre-coated plates with a plating medium (Williams E Medium supplemented with CM3000, ThermoFisher Scientific) for 5 hours in a 5% CO₂ atmosphere at 37°C. Then, this medium was changed to a maintenance solution (CM4000 ThermoFisher Scientific) for 24 hours before starting the treatment. As before, primary hepatocytes were cultured for 24 hours with BSA-conjugated oleate (250mM) or BSA alone, with or without TRAIL (1 ng/mL). Total intracellular lipid content was evaluated by Oil-Red-O staining.

Statistics

Results are expressed as means \pm standard error of the mean (SEM). Differences in the mean among groups were analyzed using one-way or two-way ANOVA. Pairwise multiple comparisons were made using Bonferroni post-hoc analysis. A threshold of p<0.05 was considered statistically significant.

Results

Animal model and in vivo bioavailability of TRAIL

Mice were put on a high-fat dietary regime to induce obesity and associated metabolic comorbidities (**Figure 1A**). After 4 weeks, before drug randomization, HFD mice had increased in weight $(6.3 \pm 0.6 \text{ g})$ as compared to CNT mice $(3.7 \pm 0.6 \text{ g})$; p<0.05 vs HFD). HFD mice weighed 30.4 ± 0.5 g and CNT mice weighed 28.9 ± 0.7 g. There were no differences between the groups in terms of fasting glucose and insulin. Nevertheless, the glucose and insulin tolerance tests showed that HFD mice had developed impaired glucose tolerance as compared to CNT mice (**Figure 1B**). At this stage, HFD mice were randomized to receive either TRAIL or saline by weekly IP injection for 8 weeks. This schedule was chosen based on our previous study (7). Mice tolerated this treatment well, and they did not show any sign of distress during the study or gross abnormalities at necroscopic examination as compared to those treated with saline, in line with previous reports (18). When we then looked at TRAIL bioavailability, we found that TRAIL was detectable after 6 hours from the IP injection and then disappeared 24 hours later. This data was in line with our imaging experiment showing that the highest fluorescence signal of Cy5.5-TRAIL was detected 6 hours after the IP injection, and then tended to decrease over time (**Figure 1C-D**).

TRAIL treatment significantly reduced obesity, as well as adipose and systemic inflammation

At the end of the study, HFD mice became obese as compared to CNT mice. TRAIL treatment significantly reduced body weight gain in HFD mice (**Figure 2A**), without affecting their food and energy intake. In particular, HFD mice ate 2.7 ± 0.2 g/day with an energy intake of 13.7 ± 1.2 Kcal/day, as compared to HFD+TRAIL mice, who ate 2.6 ± 0.3 g/day with an energy intake of 13.4 ± 1.3 Kcal/day. Secondly, HFD mice exhibited WAT hypertrophy, as assessed by pgWAT weight

(**Figure 2B**), which is considered one of the largest visceral WAT depots (19). This was associated with an increase in the adipocyte area (**Figure 2C-E**) and the number of infiltrating macrophages (**Figure 2E-F**). TRAIL treatment significantly reduced WAT hypertrophy, adipocyte area, and macrophage accumulation in the WAT (**Figure 2B-F**). Thirdly, HFD mice exhibited higher levels of NEFA and CRP (**Figure 2G-I**), in line with the concept that excess fat is associated with high levels of NEFA (20) and a low-grade systemic inflammatory state (21). TRAIL treatment significantly reduced both NEFA and CRP (**Figure 2G-I**). Interestingly, TRAIL treatment was associated with a significant increase in total cholesterol, driven by an increase in HDL cholesterol.

TRAIL treatment significantly reduced impaired glucose tolerance.

The tolerance tests (**Figure 3A-F**) performed at the end of the study showed that the HFD resulted in impairment of glucose clearance, leading to significant hyperglycemia and hyperinsulinemia 2 hours after a glucose load (**Figure 3D-E**). This was associated with the inability of insulin to lower glucose levels to the levels of CNT mice (**Figure 3F**). At fasting, glucose did not differ between the groups, and HFD mice displayed only a significant hyperinsulinemia as compared to CNT mice (**Figure 3G**), indicating the presence of an insulin resistance with impaired glucose tolerance. This data was consistent with the lack of significant changes in β -cell mass and density (**Figure 3H; Supplementary Figure 1**). TRAIL treatment significantly reduced both impaired glucose tolerance and insulin resistance (**Figure 3A-G**).

TRAIL treatment significantly reduced NAFLD

To understand why TRAIL reduced impaired glucose tolerance, we looked at the tissues regulating glucose metabolism, focusing on the liver and skeletal muscle (22). At the end of the study, the HFD regime did not increase the deposition of fat (lipid droplets) in the skeletal muscle, as assessed by Oil-

Red-O staining (data not shown). By contrast, when we looked at the liver, HFD mice developed significant steatosis (lipid accumulation >10% of tissue area), which was assessed by Oil-Red-O staining and by TG content quantification (**Figure 4 A-C**). The accumulation of more than 5-10% of fat in the liver, without any primary cause such as viral hepatitis, alcoholic disease, or drug-induced liver injury is what defines histologically non-alcoholic fatty liver disease (NAFLD) (23). In our study, HFD mice also exhibited a significant increase in liver macrophage infiltration (**Figure 4C-D**), but no fibrosis, which should appear after about 50 weeks of HFD (12). TRAIL treatment significantly reduced liver steatosis as well as inflammation, therefore ameliorating HFD-induced NAFLD.

TRAIL significantly increased PGC-1α expression in the liver

In parallel studies, we quantitated liver mRNA encoding transcription factors and metabolic enzymes involved in *de novo* lipogenesis, fatty acid oxidation, glucose metabolism, and mitochondrial function, as well as pro-oxidative and proinflammatory molecules. In the liver, HFD significantly increased the gene expression of *Fas*, *Ppary*, and *Il-6*, while it decreased that of *Cpt1a*, *Pepck*, and *Pgc-1a*, as compared to CNT mice (**Table 1**). In HFD mice, TRAIL significantly decreased the gene expression of *Fas* and *Il-6*, while it increased that of *Ppary* and *Pgc-1a* (**Table 1**; **Figure 4E-F**). The increase in *Ppary* and *Pgc-1a* gene expression that followed TRAIL treatment was observed only in the liver (**Supplementary Figure 2A**). Given that PGC-1a regulates energy metabolism and could explain part of our findings, we further evaluated it by immunostaining. In HFD mice, PGC-1a protein expression increased and changed pattern of distribution as compared to CNT mice, where it was located in the nuclei. TRAIL further increased PGC-1a protein expression in the liver (**Figure 4C and Figure 4G**). In addition, we quantitated liver mRNA encoding for *Atg7*, which is a protein essential for autophagy, a process that has been recently implicated in lipid metabolism regulation (24). Interestingly, an increase in *Atg7* was observed in the liver of HFD+TRAIL mice (**Table 1**; **Supplementary Figure 2A**)

TRAIL significantly reduced lipid droplet accumulation in hepatocytes cultured in a high-fat diet

278 milieu

To determine whether TRAIL had direct effects on hepatocytes, we used an *in vitro* model of NAFLD (9), and cultured HepG2 cells with either palmitate or oleate. It must be noted that, although HepG2 cells are derived from liver hepatocellular carcinoma and they express TRAIL receptors (Supplementary Figure 2B), they are normally resistant to TRAIL-induced apoptosis (25). MTT assay showed that palmitate significantly impaired HepG2 cell viability, while oleic acid had no effect on it (Figure 5A). In HepG2 cells cultured with oleic acid, TRAIL treatment promoted cell viability (Figure 5A), which is consistent with earlier observations that TRAIL can also activate survival pathways (26). Most importantly, in these cells, TRAIL treatment reduced lipid droplet accumulation by 45% (Figure 5B-C). This effect was confirmed in primary hepatocytes, where TRAIL treatment reduced lipid droplet accumulation by 39% (Figure 5B-C). In addition, in HepG2 cells cultured with oleic acid, TRAIL upregulated *PPARγ*, *PGC-1α*, and *ATG7* gene expression (Figure 6A-C), as well as PGC-1α protein expression (Figure 6D), while it had no effect on specific proinflammatory markers (Supplementary Figure 2C).

Discussion

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

The first new finding of this study is that TRAIL significantly ameliorated diet-induced metabolic abnormalities even when it was administered after the development of impaired glucose tolerance. At the end of the study, HFD mice became obese and insulin resistant, displaying impaired glucose tolerance as well as an increase in NEFA and CRP levels. By comparison, the group of HFD+TRAIL mice showed a significant reduction in body weight gain, NEFA and CRP levels, as well as a significant amelioration of insulin resistance and impaired glucose tolerance. Looking at the adipose tissue, TRAIL reduced body weight gain, which was associated with a decrease in fat weight, adipocyte size, and pgWAT macrophage infiltration. These findings are consistent with the earlier observations that TRAIL had significant effects on body weight. As a matter of fact, genetic TRAIL deficiency was found to be associated with increased body weight (8), and we reported that TRAIL treatment significantly reduced the adiposity of HFD-fed mice as assessed by EchoMRI (7). More recently, it has been shown that TRAIL has the ability to inhibit adipogenic differentiation through caspase activation (27). When interpreting our results in light of this finding, it is also by reducing fat mass that TRAIL could have ameliorated insulin resistance, impaired glucose tolerance, as well as circulating NEFA and CRP in HFD mice. Excess fat mass has been associated not only with insulin resistance (20), but also with high levels of NEFA (20) and a low-grade systemic inflammatory state (21). Moreover, experimental studies have shown that insulin sensitivity and systemic inflammation improve following adipose tissue removal (28). In this study, HFD mice developed also hepatic steatosis and inflammation, corresponding to human non-alcoholic fatty liver disease (NAFLD). At present, NAFLD is found to be a frequent comorbid factor in the setting of type 2 diabetes (29, 30). It is estimated that about 70% of obese patients with diabetes have NAFLD and as many as 30-40% have non-alcoholic steatohepatitis (NASH), which is characterized by hepatic steatosis with inflammation and/or necrosis (30). Both NAFLD and NASH are conditions leading to hepatic cirrhosis, end-stage liver disease, and hepatocellular carcinoma (29). Given that NAFLD is reaching epidemic proportions in diabetic patients (29, 30), it is predicted that cirrhosis related to NASH will surpass HCV-related cirrhosis as the most common indication for liver transplantation in the United States (31). Therefore, the second important finding of this study is that TRAIL treatment markedly reduced NAFLD in the HFD-fed mouse, where it decreased liver fat content by 47%. Given that NAFLD generally promotes metabolic abnormalities (29, 30), it is also by reducing liver fat content that TRAIL might have ameliorated insulin resistance and subclinical inflammation in HFD-fed mice. To date, only a few studies have addressed the relationship between TRAIL and NAFLD (9, 32). By comparison, this is the first study describing the direct effect of TRAIL in an experimental model of NAFLD. Nevertheless, our data is consistent with the finding that TRAIL deficiency worsens NAFLD (9). There seem to be several mechanisms underlying TRAIL actions on the liver. First, the reduction in body weight gain, fat mass, and circulating NEFA, which were induced by TRAIL, could have ameliorated NAFLD in the HFD+TRAIL group. It has been argued that excess storage of hepatic triglycerides comes mostly from an excess of circulating NEFA (33), which is usually associated with visceral obesity (34) or adipose tissue insulin resistance/inflammation (34, 35). Second, the significant reduction of insulin, which was observed in the HFD+TRAIL group, could have also contributed to NAFLD amelioration. Hyperinsulinemia usually contributes to liver steatosis. Insulin promotes the synthesis and inhibits the degradation of lipids (36). It stimulates key lipogenic genes in the liver, such as fatty acid synthase (FAS), while reducing CPT1, which is the transporter of NEFA into mitochondria, thereby reducing fatty acid oxidation (36). FAS inhibitors have proven useful to reduce liver triglyceride content (37). In this study, HFD mice displayed an upregulation of Fas and a

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

downregulation of *Cpt1a* in the liver. TRAIL significantly reduced HFD-induced *Fas* upregulation, consistent with the reduction of insulin and liver steatosis. Third, this study clearly shows that TRAIL also has direct actions on hepatocytes, where it significantly decreased fat content.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

In this study, TRAIL significantly reduced lipid droplet accumulation in both HepG2 cells and primary hepatocytes cultured with oleate. Our results are consistent with the observation that TRAIL treatment reduces palmitate-induced lipid uptake by 30% in hepatocytes (9). Interestingly, in this study, TRAIL promoted hepatocyte cell viability and did not have anti-inflammatory effects in vitro, suggesting that the in vivo reduction of liver inflammation might be secondary to the amelioration of steatosis. In addition, TRAIL showed a direct stimulatory effect on liver *Ppary* and PGC-1a expression in vivo, which was confirmed *in vitro*, where TRAIL significantly increased *PPARγ* and PGC-1α expression in HepG2 cells. PPARy is a nuclear receptor expressed in adipose tissue, muscle, and liver. Several studies have shown that PPARy agonists significantly reduce hepatic triglyceride content and NAFLD in patients with diabetes (38, 39). There is a functional interaction between PPARy and PGC-1a, which might explain the parallel increase of their gene expression induced by TRAIL (40, 41). PGC-1α, which is a transcriptional coactivator of nuclear receptors, is currently considered as a key component of regulatory networks that control cellular actions to adapt to higher cellular demands, such as mitochondrial function, gluconeogenesis and glucose transport, glycogenolysis, and fatty acid oxidation (42). Interestingly, PGC-1α polymorphisms have been associated with obesity and increased risk of diabetes (43, 44). Moreover, both PGC-1α (45) and PGC-1α-responsive genes are coordinately downregulated in human diabetes (46). When looking at the liver, it has been shown that PGC-1 α deficient mice (47) and liver-specific PGC-1α heterozygous mice (48) develop hepatic steatosis. Moreover, PGC-1α seems to have a suppressive effect on liver inflammation (49). Therefore, our results suggest that TRAIL effects on the liver and glucose metabolism might involve PPARy and/or PGC-1α actions.

In addition, based on our *in vitro* studies, where TRAIL increased ATG7, a possible unifying hypothesis explaining TRAIL effects on liver steatosis and PGC-1 α is that they might be due to TRAIL-induced liver autophagy (50). Autophagy is a mechanism by which TG content, lipid droplet number and size is regulated. In this process, lipids are sequestered in autophagosomes where they are degraded (24). This should stimulate mitochondrial β -oxidation (24). Moreover, autophagy seems to regulate the flux of cholesterol out of the cell to APOA-I (51), which is the major component of HDL and could explain the increase in HDL cholesterol that we found in HFD+TRAIL mice. Further studies are needed to evaluate the mechanisms underlying TRAIL effect on liver steatosis and PGC-1 α , as well as to test in detail the hypothesis that they might include TRAIL actions on liver autophagy.

abnormalities even when it was administered after the development of impaired glucose tolerance.

Second, this study shows that TRAIL markedly improved NAFLD in HFD-fed mice, and that this was

associated with a significant increase in PGC-1a. Overall, our results shed light on the therapeutic

potential of TRAIL against diabetes, NAFLD, and NASH.

Perspective

- Experimental evidence suggests that a circulating protein called TRAIL protects against type 2 diabetes. This study was designed to evaluate whether TRAIL had the potential not only to prevent, but also to treat diet-induced type 2 diabetes.
 - Our *in vivo* results show that TRAIL had the ability to attenuate the metabolic abnormalities induced by a high-fat diet, also when TRAIL was given after disease onset (after 4 weeks of high-fat diet). In particular, TRAIL treatment significantly reduced body weight, impaired glucose tolerance, and liver steatosis, all of which are frequently associated with type 2 diabetes.
 - Our *in vitro* results show that TRAIL has direct effects on hepatocytes, where it reduces lipid
 droplet accumulation. This data sheds light on TRAIL therapeutic potential against impaired
 glucose tolerance and NAFLD.

Acknowledgements

391

395

396

397

- We acknowledge Dr. Barbara Dapas (Department of Life Sciences Università degli Studi di Trieste.
- 393 Italy) for her technical support in *in vitro* experiments, as well as the Foundation "Dott. Carlo
- 394 Fornasini" (Poggio Renatico, Ferrara, Italy).

Declarations of interest

All Authors have no conflicts of interest.

Funding

- 398 This work was supported by research funding from Italian Ministry of Health to Stella Bernardi (GR-
- 399 2013-02357830), and to V.T. (GR-2010-2310832), and from Università degli Studi di Trieste to B.F.
- 400 (FRA-2012).

401 Author contribution

- S. Bernardi conception and design, acquisition, analysis and interpretation of data, and drafting the
- article; B.T. acquisition, analysis and interpretation of data and drafting article; V.T. F.B. S. Biffi and
- 404 A.L. acquisition, analysis and interpretation of data; G.Z. P.S. conception, interpretation of data and
- article revision for important intellectual content; B.F. conception and design, and article revision for
- 406 important intellectual content. All the authors have read and approved the submission of this
- 407 manuscript.

References

410

- 411 1. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin
- 412 Invest. 2008;118(6):1979-90.
- 413 2. Harith HH, Morris MJ, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab.
- 414 2013;24(11):578-87.
- 3. Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B. TRAIL modulates the immune system and protects
- against the development of diabetes. J Immunol Res. 2015;2015:680749.
- 417 4. Mi QS, Ly D, Lamhamedi-Cherradi SE, Salojin KV, Zhou L, Grattan M, et al. Blockade of tumor necrosis
- factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes. 2003;52(8):1967-
- 419 75.
- 420 5. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor-related
- apoptosis-inducing ligand in type 1 diabetes. Diabetes. 2003;52(9):2274-8.
- 422 6. Zauli G, Toffoli B, di Iasio MG, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor
- 423 necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.
- 424 Diabetes. 2010;59(5):1261-5.
- 425 7. Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P, et al. TNF-related apoptosis-inducing
- 426 ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic
- 427 inflammation. Clin Sci (Lond). 2012;123(9):547-55.
- 428 8. Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE, et al. TNF-related apoptosis-inducing
- 429 ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe (-)/(-) mice. Diabetologia.
- 430 2011;54(12):3157-67.
- 431 9. Cartland SP, Harith HH, Genner SW, Dang L, Cogger VC, Vellozzi M, et al. Non-alcoholic fatty liver
- disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice. Sci Rep.
- 433 2017;7(1):1898.
- 434 10. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of
- impaired glucose tolerance and type 2 diabetes. Diabetes. 2004;53 Suppl 3:S215-9.
- 436 11. King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877-94.
- 437 12. Ito M, Suzuki J, Tsujioka S, Sasaki M, Gomori A, Shirakura T, et al. Longitudinal analysis of murine
- 438 steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res. 2007;37(1):50-7.
- 439 13. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification
- and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 1997;272(41):25417-
- 441 20.
- 442 14. Tisato V, Garrovo C, Biffi S, Petrera F, Voltan R, Casciano F, et al. Intranasal administration of
- 443 recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model.
- 444 PLoS One. 2014;9(12):e115387.
- 445 15. Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, et al. Osteoprotegerin induces
- morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol. 2011;331(1):136-42.
- 447 16. Bernardi S, Tikellis C, Candido R, Tsorotes D, Pickering RJ, Bossi F, et al. ACE2 deficiency shifts energy
- 448 metabolism towards glucose utilization. Metabolism. 2015;64(3):406-15.
- 449 17. Severgnini M, Sherman J, Sehgal A, Jayaprakash NK, Aubin J, Wang G, et al. A rapid two-step method
- 450 for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor
- 451 based assay development. Cytotechnology. 2012;64(2):187-95.
- 452 18. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, et al. Systemic tumor necrosis
- 453 factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null
- 454 diabetic mice. Circulation. 2006;114(14):1522-30.

- 455 19. Sanchez-Gurmaches J, Hung CM, Guertin DA. Emerging Complexities in Adipocyte Origins and Identity.
- 456 Trends Cell Biol. 2016;26(5):313-26.
- 457 20. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med.
- 458 2017;376(3):254-66.
- 459 21. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in
- 460 overweight and obese adults. JAMA. 1999;282(22):2131-5.
- 461 22. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the
- treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
- 463 23. Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and
- 464 hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol.
- 465 2015;21(46):12989-95.
- 466 24. Liu K, Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ. 2013;20(1):3-
- 467 11.
- 468 25. Sun J, Yu X, Wang C, Yu C, Li Z, Nie W, et al. RIP-1/c-FLIPL Induce Hepatic Cancer Cell Apoptosis Through
- 469 Regulating Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). Med Sci Monit. 2017;23:1190-9.
- 470 26. Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential
- 471 cardioprotective activity. Invest New Drugs. 2012;30(3):1257-60.
- 472 27. Zoller V, Funcke JB, Keuper M, Abd El Hay M, Debatin KM, Wabitsch M, et al. TRAIL (TNF-related
- 473 apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of
- adipogenic transcription factors. Cell Death Dis. 2016;7(10):e2412.
- 475 28. Pitombo C, Araujo EP, De Souza CT, Pareja JC, Geloneze B, Velloso LA. Amelioration of diet-induced
- diabetes mellitus by removal of visceral fat. J Endocrinol. 2006;191(3):699-706.
- 477 29. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol.
- 478 2017;14(1):32-42.
- 479 30. Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current
- approaches and future directions. Diabetologia. 2016;59(6):1112-20.
- 481 31. Ge PS, Runyon BA. Treatment of Patients with Cirrhosis. N Engl J Med. 2016;375(8):767-77.
- 482 32. Idrissova L, Malhi H, Werneburg NW, LeBrasseur NK, Bronk SF, Fingas C, et al. TRAIL receptor deletion
- 483 in mice suppresses the inflammation of nutrient excess. J Hepatol. 2015;62(5):1156-63.
- 484 33. Donnelly KL, Smith Cl, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in
- 485 liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest.
- 486 2005;115(5):1343-51.
- 487 34. Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, et al. Mechanisms and
- 488 metabolic implications of regional differences among fat depots. Cell Metab. 2013;17(5):644-56.
- 489 35. Perry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, et al. Hepatic acetyl CoA links
- 490 adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745-58.
- 491 36. Weickert MO, Pfeiffer AF. Signalling mechanisms linking hepatic glucose and lipid metabolism.
- 492 Diabetologia. 2006;49(8):1732-41.
- 493 37. Wu M, Singh SB, Wang J, Chung CC, Salituro G, Karanam BV, et al. Antidiabetic and antisteatotic effects
- of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad
- 495 Sci U S A. 2011;108(13):5378-83.
- 496 38. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, et al. The effects of rosiglitazone on
- 497 insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2
- 498 diabetes. Diabetes. 2002;51(3):797-802.
- 499 39. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-Term Pioglitazone Treatment for
- Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
- 501 Ann Intern Med. 2016;165(5):305-15.

- 502 40. Fujisawa K, Nishikawa T, Kukidome D, Imoto K, Yamashiro T, Motoshima H, et al. TZDs reduce
- 503 mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun.
- 504 2009;379(1):43-8.
- Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of
- nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92(6):829-39.
- Wu H, Deng X, Shi Y, Su Y, Wei J, Duan H. PGC-1alpha, glucose metabolism and type 2 diabetes mellitus.
- 508 J Endocrinol. 2016;229(3):R99-R115.
- 509 43. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, et al. Mutation analysis of
- 510 peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino
- acid polymorphisms to Type II diabetes mellitus. Diabetologia. 2001;44(12):2220-6.
- Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, et al. A genetic variation in the PGC-1 gene
- could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 2002;45(5):740-3.
- 514 45. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al. Coordinated reduction of genes of
- oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc
- 516 Natl Acad Sci U S A. 2003;100(14):8466-71.
- 517 46. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive
- genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet.
- 519 2003;34(3):267-73

532

- Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, et al. PGC-1alpha deficiency causes
- 521 multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic
- 522 steatosis. PLoS Biol. 2005;3(4):e101.
- 523 48. Estall JL, Kahn M, Cooper MP, Fisher FM, Wu MK, Laznik D, et al. Sensitivity of lipid metabolism and
- 524 insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma
- 525 coactivator-1alpha expression. Diabetes. 2009;58(7):1499-508.
- 526 49. Barroso WA, Victorino VJ, Jeremias IC, Petroni RC, Ariga SKK, T AS, et al. High-fat diet inhibits PGC-
- 527 1alpha suppressive effect on NFkappaB signaling in hepatocytes. Eur J Nutr. 2017.
- 528 50. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and
- 529 autophagy. Biochim Biophys Acta. 2013;1833(12):3448-59.
- 530 51. Ouimet M, Franklin V, Mak E, Liao X, Tabas I, Marcel YL. Autophagy regulates cholesterol efflux from
- macrophage foam cells via lysosomal acid lipase. Cell Metab. 2011;13(6):655-67.

534 Tables

Table 1. Liver gene expression analysis

	CNT	HFD	HFD + TRAIL	HFD vs CNT	HFD + TRAIL	HFD vs HFD
					vs CNT	+ TRAIL
		De	e novo lipogene.	sis		
Fas	1.00 ± 0.10	1.60 ± 0.11	1.20 ± 0.07	<0.01	NS	<0.05
Srebp1a	1.00 ± 0.04	1.17 ± 0.10	1.16 ± 0.11	NS	NS	NS
Srebp1c	1.00 ± 0.20	0.70 ± 0.06	1.17 ± 0.21	NS	NS	NS
		Fa	itty acid oxidati	on		
Aox	1.00 ± 0.08	0.77 ± 0.06	0.83 ± 0.07	NS	NS	NS
Cpt1a	1.00 ± 0.06	0.51 ± 0.07	0.55 ± 0.07	<0.0001	<0.0001	NS
Pparα	1.00 ± 0.11	0.75 ± 0.14	0.85 ± 0.15	NS	NS	NS
	Glu	iconeogenesis,	insulin signaling	, insulin sensitiv	vity	
Irs2	1.00 ± 0.09	0.79 ± 0.08	0.74 ± 0.12	NS	NS	NS
Pepck	1.00 ± 0.10	0.30 ± 0.09	0.32 ± 0.06	<0.0001	<0.0001	NS
Ppary	1.00 ± 0.10	1.82 ± 0.21	2.57 ± 0.20	<0.01	<0.0001	<0.05
Hnf4	1.00 ± 0.11	0.99 ± 0.11	1.07 ± 0.09	NS	NS	NS
		Mit	ochondrial func	tion		
Cit synt	1.00 ± 0.09	1.00 ± 0.11	1.12 ± 0.08	NS	NS	NS
Pgc-1α	1.00 ± 0.05	0.41 ± 0.05	0.65 ± 0.03	<0.0001	<0.0001	<0.01
PIn5	1.00 ± 0.21	0.72 ± 0.07	0.81 ± 0.08	NS	NS	NS
Ucp2	1.00 ± 0.11	0.69 ± 0.07	0.79 ± 0.11	NS	NS	NS
Sirt-1	1.00 ± 0.07	1.06 ± 0.10	1.03 ± 0.06	NS	NS	NS
		ı	stress and inflo	ı		
Gp91phox	1.00 ± 0.13	0.83 ± 0.15	0.86 ± 0.16	NS	NS	NS
II-6	1.00 ± 0.18	1.74 ± 0.14	1.16 ± 0.10	<0.01	NS	<0.05
Мср1	1.00 ± 0.20	1.95 ± 0.25	1.99 ± 0.38	NS	NS	NS
Tnfα	1.00 ± 0.14	0.82 ± 0.12	1.14 ± 0.23	NS	NS	NS
			Autophagy			
Atg7	1.00 ± 0.06	1.33 ± 0.12	1.53 ± 0.11	<0.05	<0.01	NS

Fatty acid synthase (Fas), sterol regulatory element binding protein-1a (Srebp1a), and sterol regulatory element binding protein-1c (Srebp1c) are transcription factors and enzymes involved in lipogenesis. Acyl-CoA oxidase (Aox), carnitine palmitoyl transferase-1a (Cpt1a), and peroxisome proliferator-activated receptora (Ppara) are transcription factors and enzymes involved in fatty acid oxidation. Irs2 regulates insulin signaling; Pepck regulates gluconeogenesis; peroxisome proliferator-activated

receptory ($Ppar\gamma$) sensitizes to insulin. Hepatocyte nuclear factor 4 (Hnf4) is a transcriptional regulator of gluconeogenic genes. Citrate synthase ($Cit\ synt$), which is the pace-making enzyme of Krebs cycle, and uncoupling protein2 (Ucp2) are localized in mitochondria, while PPAR γ coactivator 1α ($Pgc-1\alpha$), perilipin 5 (Pln5), and sirtuin-1 (Sirt-1) regulate mitochondrial functions. Gp91phox is a subunit of NADPH oxidase, which is involved in oxidative stress, interleukin-6 (Il-6), monocyte chemoattractant protein-1 (Mcp1), and $Tnf\alpha$ are proiflammatory mediators. Autophagy-related protein 7 (Atg7) is a molecule involved in autophagy.

Figure legends

- Figure 1. Treatment protocol. (A) Schematic illustration of the protocol: C57BL/6J mice were fed 551 either a standard diet (SD; 12% fat) or a high-fat diet (HFD; 60% fat) for 12 weeks. Mice on HFD were 552 treated either with saline (NaCl 0.9%) or TRAIL weekly between week 5 and week 12. Mice on SD 553 554 were treated with saline. (*) Tolerance tests before drug randomization; (**) Tolerance tests at the end of the study (B) Glucose and insulin tolerance tests performed before drug randomization. Upper 555 figures show blood glucose and its area under the curve (AUC) during an IPGTT, middle figures show 556 serum insulin and its AUC during an IPGTT, lower figures show blood glucose and its AUC during an 557 IPITT (C) Representative images of Cy5.5-TRAIL clearance from the peritoneal cavity, as assessed by 558 acquisition of fluorescence emission from the peritoneum after an IP injection of 10 µg of Cy5.5-559 TRAIL. Cy5.5-TRAIL is TRAIL that was labeled with N-hydrosuccinimmide ester of the cyanine 5.5. 560 Fluorescence emission was collected at 700 nm. For further details, see (14). (**D**) Circulating human 561 TRAIL after IP injection of 10 µg of TRAIL. 562 563 Figure 2. Body weight, adipose tissue, and inflammation. (A) Body weight throughout the study. The gray area corresponds to the treatment period. (B) Perigonadal white adipose tissue (pgWAT) 564 weight at the end of the study. (C-D) Frequency distribution and adipocyte area. (E) Representative 565 images of pgWAT H&E staining (upper panel; 12.5x, scale bar 50 μm) and F4/80+ macrophages 566 (lower panels; 25x, scale bar 50 μm). (G) NEFA levels at the end of the study. (H) Total cholesterol 567 568 (TC), HDL cholesterol (HDL-C), and triglycerides (TG) at the end of the study. (I) C-reactive protein levels at the end of the study. Results are presented as mean \pm SEM; * p<0.05 vs CNT; # p<0.05 vs 569 HFD. 570
- Figure 3. Glucose metabolism. (A-F) Glucose and insulin tolerance tests performed at the end of the study. (A) Blood glucose during an IPGTT; (B) Serum insulin during an IPGTT; (C) Blood glucose

during an IPITT; **(D)** Area under the curve (AUC) of the glucose levels during the IPGTT; **(E)** AUC of the insulin levles during the IPGTT; **(F)** AUC of the glucose levels during the IPITT; **(G)** Fasting glucose and insulin ant the end of the study. **(H)** Representative images of pancreatic sections immunostained for insulin (25x, scale bar 50 μ m). Results are presented as mean \pm SEM; * p<0.05 vs CNT; # p<0.05 vs HFD.

Figure 4. Liver changes. (A) Liver triglyceride content; (B) Percentage of hepatic area positive for fat (stained red) with Oli-Red-O (ORO). (C) Representative images of liver ORO staining (25x, scale bar 50 μm), Picrosirius Red (Sirius Red) staining (12.5X, scale bar 100 μm), CD68+ macrophages (12.5X, scale bar 100 μm), and PGC-1α staining (12.5X, scale bar 100 μm). (D) Quantification of CD68+ cells (brown nuclei)/frame liver tissue. (E) Liver mRNA expression of *II-6. II-6* is for interleukin-6. mRNA expression is reported as fold induction standardized to the mRNA expression in CNT mice. (F) Liver mRNA expression of $Pgc-1\alpha$. $Pgc-1\alpha$ is for peroxisome proliferator-activated receptor-γ coactivator-1 alpha. mRNA expression is reported as fold induction standardized to the mRNA expression in CNT mice. (G) Quantification of PGC-1α + staining (brown)/area of liver tissue. Results are presented as mean ± SEM; * p<0.05 vs CNT; # p<0.05 vs HFD.

Figure 5. **Hepatic lipid droplet accumulation** *in vitro*. **(A)** HepG2 cell viability after exposure to palmitic acid or oleic acid in presence or absence of TRAIL. **(B)** HepG2 and mPH percentage of cell surface positive for lipid droplets (dark red staining) with Oil-Red-O (ORO). Cells were incubated with oleic acid (250 μ M) in presence or absence of TRAIL (1 ng/mL). HepG2 is for HepG2 cells and mPH is for mouse primary hepatocytes. **(C)** Representative images of HepG2 cells (upper panel) and mouse primary hepatocytes (lower panel) stained with ORO (20x, scale bar 100 μ m). Results are presented as mean \pm SEM; * p<0.05 vs control; # p<0.05 vs oleic acid without TRAIL.

- **Figure 6. In vitro studies on HepG2 cells**. **(A)** HepG2 cell mRNA expression of *PPARγ*; **(B)** *PGC-1α*;
- 596 (C) ATG7. (D) Representative images of PGC-1α immunostaining on HepG2 cells. Results are
- presented as mean \pm SEM; * p<0.05 vs control without TRAIL.





Figure 1

Figure 2









Figure 4







Supplementary Materials and Methods

Recombinant human TRAIL (rhTRAIL) preparation

Recombinant soluble human TRAIL (His6-tagged TRAIL) was produced in bacteria as described by MacFarlane (1997) and purified by affinity chromatography on Ni2+ affinity resin (Qiagen, Hilden, Germany). Determination of total protein concentration in the fractions collected after dialysis was performed using a bicinchoninic protein assay with bovine serum albumin as the standard, accordingly to the manufacturer's instructions (Thermo Fisher Scientific Inc., Rockford, USA). TRAIL concentration was then quantified by ELISA (R&D Systems, Minneapolis, Minn., USA; sensitivity: 2.9 pg/ml; intra- and interassay CV were 3.9 and 6%, respectively) in duplicate samples. Selected samples were run in each ELISA plate as internal controls to confirm the reproducibility of the determinations over time. The functional activity of each TRAIL preparation was tested on the TRAIL-sensitive HL60 cell line by evaluating cell viability and apoptosis after treatment of the cells with serial dilutions of each preparation. Finally, purified TRAIL batches were tested for the absence of endotoxin by using the ToxinSensor chromogenic LAL endotoxin assay kit (GenScript, Piscataway, NJ) and stored at -80°C in single use aliquots.

Labeling of rhTRAIL

Purified rhTRAIL was labeled with N-hydroxisuccinimide ester of the cyanine 5.5 (Amersham Biosciences; FluorolinkCy5.5 Monofunctional Dye 5-pack) to form TRAIL-Cy5.5. A freshly prepared solution of dye (0.05 mg/mL) in 0.1M sodium carbonate buffer pH 8 was added to rhTRAIL (1 mg/mL) in phosphate buffer (vol/vol 1:1). The reagents were incubated by gently shaking for 1 hour at room temperature. Excess unconjugated dye was removed by overnight dialysis against phosphate buffer pH 7.4.

Triglyceride measurement with the Beckman Coulter AU5800 analyzer

The procedure for the determination of triglyceride concentration with the Beckman Coulter AU5800 analyzer is based on a series of coupled enzymatic reactions. The triglyceride in the sample are hydrolyzed by a combinantion of microbial lipases to give glycerol and fatty acids. The glycerol is phosphorylated by ATP in the presence of glycerol kinase to produce glycerol-3-phosphate. The glycerol-3-phosphate is oxidized by molecular oxygen in the presence of glycerol phosphate oxidase to produce hydrogen peroxide (H₂O₂) and dihydroxyacetone phosphate. The formed H₂O₂ reacts with 4-aminophenazone and N,N-bis(4-sulfobutyl)-3,5-dimethylaniline, disodium salt (MADB) in the presence of peroxidase (POD) to produce a chromophore, which is red at 660/880 nm. The increase in absorbance at 660/800 nm is proportional to the triglyceride content of the sample.

Supplementary Table 1. Sequences of probes/primer pairs

Gene	Primer pair			
Mouse				
Rps9	(F) 5'-GACCAGGAGCTAAAGTTGATTGGA-3'			
	(R) 5'-TCTTGGCCAGGGTAAACTTGA-3'			
Fas	(F) 5'-TCGTGATGAACGTGTACCGG-3'			
	(R) 5'- GGGTGAGGACGTTTACAAAG-3'			
Srebp1a	(F) 5'-ATGGACGAGCTGGCCTTCG-3'			
	(R) 5'- TGTTGATGAGCTGGAGCATGTCTTC-3'			
Srebp1c	(F) 5'-ATGGATTGCACATTTGAAGACATGCT-3'			
	(R) 5'- CCTGTGTCCCCTGTCTCAC-3'			
Aox	(F) 5'-TCACGTTTACCCCGGC-3'			
	(R) 5'- CAAGTACGACACCATACCAC-3'			
Cpt1a	(F) 5'-CCAAGTATCTGGCAGTCGA-3'			
	(R) 5'-CGCCACAGGACACATAGT-3'			
Pparα	(F) 5'-TCAAGGTGTGGCCCAAGGTTA-3'			
	(R) 5'-CGAATGTTCTCAGAAGCCAGCTC-3'			
Irs2	(F) 5'-GACTTCCTGTCCCATCACTTG-3'			
	(R) 5'-TTTCAACATGGCGGCGA-3'			
Pepck	(F) 5'-CCATCCCAACTCGAGATTCTG-3'			
	(R) 5'- CTGAGGGCTTCATAGACAAGG-3'			
Ppary	(F) 5'-TGTCGGTTTCAGAAGTGCCTTG-3'			
	(R) 5'-TTCAGCTGGTCGATATCACTGGAG-3'			
Hnf4	(F) 5'-CAAGAGGTCCATGGTGTTTAAGG-3'			
	(R) 5'-CGGCTCATCTCCGCTAGCT-3'			
Cit Synt	(F) 5'-CAAGCAGCAACATGGGAAGA-3'			
	(R) 5'-GTCAGGATCAAGAACCGAAGTCT-3'			
Pgc-1α	(F) 5'-TGATGTGAATGACTTGGATACAGACA-3'			
	(R) 5'- GCTCATTGTTGTACTGGTTGGATATG-3'			
Ucp2	(F) 5'-GCCTCTGGAAAGGGAGTTCTC-3'			
	(R) 5'- ACCAGCTCAGCACAGTTGACA-3'			
gp91phox	(F) 5'-TTGGGTCAGCACTGGCTCTG-3'			
	(R) 5'-TGGCGGTGTGCAGTGCTATC-3'			
II-6	(F) 5'-ACCAGAGGAAATTTTCAATAGGC-3'			
	(R) 5'- TGATGCACTTGCAGAAAACA-3'			
Tnfα	(F) 5'-AAGCCTGTAGCCCACGTCGTA-3'			
	(R) 5'-GGCACCACTAGTTGGTTGTCTTTG-3'			
Atg7	(F) 5'-TGCCTATGATGATCTGTGTC-3'			
	(R) 5'-CACCAACTGTTATCTTTGTCC-3'			
Pln5	(F) 5'-TCTCGCCTATGAACACTCTTTG-3'			
	(R) 5'-GGGATGGAAAGTAGGGCTAG-3'			
Sirt-1	(F) 5'-TGTGAAGTTACTGCAGGAGTG-3'			
	(R) 5'-CAAGGCGAGCATAGATACCG-3'			
Human				


RPL27	(R) 5'-TGTCCTGGCTGGACGCTACT-3'		
	(F) 5'-CTGAGGTGCCATCATCAATGTT-3'		
DR4	(F) 5'-CACAAGACCTTCAAGTTTGTCG-3'		
	(R) 5'-TGGACACACTCTCCCAAAG-3'		
DR5	(F) 5'-ATCGTGAGTATCTTGCAGCC-3'		
	(R) 5'-TGAGACCTTTCAGCTTCTGC-3'		
DcR1	(F) 5'-GATTACACCAACGCTTCCAAC-3'		
	(R) 5'-TGCCTTCTTTACACTGACACAC-3'		
DcR2	(F) 5'-GTGGTTGTGGCTTTTC-3'		
	(R) 5'-CAGGAACTCGTGAAGGACATG-3'		
PPARγ	(F) 5'-AAGGCGAGGCGATCTTG-3'		
	(R) 5'-CCCATCATTAAGGAATTCATGTCA-3'		
PGC-1α	(F) 5'-AAACAGCAGCAGAGACAAATGC-3'		
	(R) 5'-TTGGTTTGGCTTGTAAGTGTTGTG-3'		
ATG7	(F) 5'-TCGAAAGCCATGATGTCGTCTT-3'		
	(R) 5'-CCAAAGCAGCATTGATGACCA-3'		
CXCL8	(F) 5'-TTCCTGATTTCTGCAGCTCT-3'		
	(R) 5'-TGTCTTTATGCACTGACATC-3'		
ΤΝΓα	(F) 5'-CAGGGACCTCTCTAATCA-3'		
	(R) 5'-GGCTACAGGCTTGTCACTCG-3'		
Gene	Probe/Primer pair		
Mouse			
Мср1	(P) FAM-5'-TCCCTGTCATGCTTCTGGGCCTGT-3'-TAMRA		
	(F) 5'-CTTCCTCCACCACCATGCA-3'		
	(R) 5'-CCAGCCGGCAACTGTGA-3'		


Supplementary Figure Legends

Supplementary Figure 1. Pancreatic beta cell density and mass. (A) Pancreatic beta cell density as assessed by percentage of islet area positive for insulin (brown staining); (B) Pancreatic beta cell mass was estimated by multiplying the mean density of staining for insulin in the islet section by the mean islet area per area of pancreas. This was adjusted for the pancreatic wet weight for individual animals and expressed as fold changes relative to CNT mice.

Supplementary Figure 2. Gene expression in *in vivo* and *in vitro* studies. (A) Liver, white adipose tissue (WAT), and skeletal muscle mRNA expression of Ppary, $Pgc-1\alpha$, and Atg7. PPARy is for peroxisome proliferator-activated receptor- γ ; PGC-1 α is for peroxisome proliferator-activated receptor- γ coactivator-1 alpha; ATG7 is for autophagy-related protein 7. mRNA expression is reported as fold induction standardized to the mRNA expression in CNT mice. Results are presented as mean \pm SEM; * p<0.05 vs CNT; # p<0.05 vs HFD. (B-C) HepG2 cell mRNA expression of TRAIL receptors (DR4, DR5, DcR1, DcR2) and proinflammatory molecules (CXCL8 and $TNF\alpha$). DR is for death receptor; DcR is for decoy receptor; CXCL8 is for chemokine (C-X-C motif) ligand 8. Cells were treated with oleic acid (250 μ M) in presence or absence of rhTRAIL (1 ng/mL) for 6 hours. For primer pairs see Supplementary Table 1.

Supplementary Figure 1





Supplementary Figure 2

